Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7524)	10/23/1998 3:31:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Well then I guess the outbreak "might" be continuing. You might want to compare the fall of 97 with the fall of 98 to be sure. If in fact this years outbreak is worse then lasts we might get a more receptive European agency) that looks at the data. All IMO.

To: aknahow who wrote (7524)	10/25/1998 9:01:00 PM
From: dlc	Read Replies (1) \| Respond to of 17367

Is it just me or does anyone else think that the UK data on the number of menningitis cases is a useless piece of data? If there is a big rise in cases there might be a public outcry and a media blitz which would be great PR for Xoma, but it says nothing about the effectiveness of the trial. The real data points we need to determine if the BPI is effective are the number of deaths and the length of illness during the trial period vs. before the trial. Since the trial is ostensibly being carried out on every patient in the UK that comes down with the illness, this data would provide very compelling proof of the effectiveness of BPI. That is the data I would like to see. Anything else seems like a complete waste of time.